



## Confidence Through Clinical and Real World Experience<sup>1-3</sup>



**#1 NOAC prescribed by Cardiologists\***

## Millions of Patients Treated Across Multiple Indications<sup>4</sup>

### References:

1. Patel M.R., Mahaffey K.W., Garg J. *et al.* Rivaroxaban versus warfarin in non-valvular atrial fibrillation. *N Engl J Med.* 2011;365(10):883–91.

2. Tamayo S., Peacock W.F., Patel M.R., *et al.* Characterizing major bleeding in patients with nonvalvular atrial fibrillation: A pharmacovigilance study of 27 467 patients taking rivaroxaban. *Clin Cardiol.* 2015;38(2):63–8. 3. Camm A.J., Amarencio P., Haas S. *et al.* XANTUS: A Real-World, Prospective, Observational Study. 4. Calculation based on IMS Health MIDAS, Database: Monthly Sales December 2015.

For full prescribing information, refer to the package insert approved by the Medicines Regulatory Authority (MCA).  XARELTO® 10 (Film-coated tablets). Reg. No.: 42/8.2/1046. Each film-coated tablet contains rivaroxaban 10 mg. **PHARMACOLOGICAL CLASSIFICATION:** A. 8.2 Anticoagulants. **INDICATION:** Prevention of venous thromboembolism (VTE) in patients undergoing major orthopaedic surgery of the lower limbs.  XARELTO® 15 and XARELTO® 20 (Film-coated tablets). Reg. No.: XARELTO® 15: 46/8.2/0111; XARELTO® 20: 46/8.2/0112. Each film-coated tablet contains rivaroxaban 15 mg (XARELTO® 15) or 20 mg (XARELTO® 20). **PHARMACOLOGICAL CLASSIFICATION:** A. 8.2 Anticoagulants. **INDICATIONS:** (1) Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (SPAF); (2) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); (3) Treatment of pulmonary embolism (PE) and for the prevention of recurrent pulmonary embolism (PE) and deep vein thrombosis (DVT).

**HCR:** Bayer (Pty) Ltd, Reg. No.: 1968/011192/07, 27 Wrench Road, Isando, 1609. Tel: 011 921 5044 Fax: 011 921 5041.

L.ZA.MKT.GM.01.2016.1265

\*Impact RX Data Oct - Dec 2015

NOAC: Non Vitamin K Oral Anticoagulant